INCYTE WKN: 896133 ISIN: US45337C1027 Kürzel: INCY Forum: Aktien Thema: Hauptdiskussion

Könnte jetzt dynamisch hoch gehen 🤪

Laut Lynx, könnte der Boden gefunden worden sein. Bin am überlegen 🤔

Jetzt muss es seine 200 tagelinie nach oben verlassen sieht ähnlich aus wie Okt. Nov 2019 dann sind locker 10-20€ Aufwärtsbewegung drin

Abgeprallt und neuer Versuch jetzt sieht es ganz gut aus wenn der s&p mal bissl hoch geht ballert das Teil auch

Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs https://www.businesswire.com/news/home/20220208005340/en/Incyte-Reports-2021-Fourth-Quarter-and-Year-End-Financial-Results-and-Provides-2022-Financial-Guidance-and-Updates-on-Key-Clinical-Programs • Total product and royalty revenues of $813 million (+20%) in Q4’21 and $2.891 billion (+17%) in FY’21 • Jakafi® (ruxolitinib) net product revenues of $592 million (+15%) in Q4’21 and $2.135 billion (+10%) in FY’21; Jakafi guidance range of $2.3 to $2.4 billion for 2022 • Successful U.S. launch of Opzelura™ (ruxolitinib) cream in atopic dermatitis with nearly 19,000 patients treated from launch (October 11th) through the end of the year • Vitiligo is the next substantial growth opportunity for ruxolitinib cream – under Priority Review in the U.S. and under review in Europe

Alter in dem Umfeld steigt das ding🤩

Erwartungen geschlagen aber den Markt enttäuscht...seltsame Sache hier

https://www.investing.com/news/stock-market-news/incyte-earnings-revenue-beat-in-q3-2663920 Incyte Earnings, Revenue Beat in Q3

Lebt die Aktie wieder? News?

Danke für die Info. Ich finde den Abverkauf aber echt heftig.

https://www.businesswire.com/news/home/20210922005863/en/Incyte-Announces-FDA-Approval-of-Jakafi%C2%AE-ruxolitinib-for-Treatment-of-Chronic-Graft-Versus-Host-Disease-GVHD

Hey DAKo, hängt sicher mit der gleichzeitigen Warnung zusammen: Incyte trades lower on safety warning in FDA approval for Opzelura https://seekingalpha.com/news/3742134-incyte-trades-lower-on-safety-warning-in-fda-approval-for-opzelura • Despite the FDA approval granted for Opzelura cream as a treatment of mild to moderate atopic dermatitis (AD), Incyte Corporation (NASDAQ:INCY) has lost ~2.5% in the pre-market after the regulator added a Boxed Warning to flag its safety concerns. • Opzelura is the first and only topical formulation of JAK (Janus kinase) inhibitors approved in the U.S., the company said. The treatment comes with the FDA’s JAK-class warning to indicate the risks of severe infections, higher risk of heart attack, stroke, etc. • The boxed warnings could hurt the long-term sales opportunity and cause a near-term reaction on company shares, Reuters reported quoting RBC analyst Brian Abraham. • The warning on Opzelura could reduce its uptake by about 30% in patients with the mild form of the disease, in particular, Abraham argues, citing a physician survey carried out by the firm. • The renewed safety concerns on the JAK class of drugs pressured AbbVie (NYSE:ABBV) early this month. The company manufactures JAK inhibitor Rinvoq (upadacitinib) indicated for rheumatoid arthritis in adults.

Das bekommen sie eine Zulassung und der Kurs bricht ein...kann mir das Mal jemand erklären?

Ich bin invistiert, Einkauf 69 Euro, 5k

So ruhig hier